Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

ORKA has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 18th. Wedbush reiterated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 12th. Finally, BTIG Research upped their target price on shares of Oruka Therapeutics from $44.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $42.00.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $15.55 on Friday. The firm’s fifty day moving average is $14.81 and its 200-day moving average is $12.19. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The firm has a market cap of $582.35 million, a P/E ratio of -5.53 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. As a group, sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Northern Trust Corp purchased a new stake in Oruka Therapeutics during the fourth quarter worth approximately $1,242,000. Jane Street Group LLC acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at approximately $343,000. Millennium Management LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter worth about $588,000. Toronto Dominion Bank bought a new position in Oruka Therapeutics during the 4th quarter worth approximately $1,131,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $236,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.